Location History:
- New Haven, CT (US) (2018)
- Billerica, MA (US) (2021 - 2023)
Company Filing History:
Years Active: 2018-2023
Title: Innovations of Momar Toure
Introduction
Momar Toure is a notable inventor based in Billerica, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that modulate proteolysis. With a total of four patents to his name, Toure's work has the potential to impact various therapeutic areas.
Latest Patents
One of Toure's latest patents is titled "Imide-based modulators of proteolysis and associated methods of use." This patent describes imide-based compounds, including bifunctional compounds, which serve as modulators of targeted ubiquitination. These compounds are particularly effective as inhibitors of various polypeptides and proteins that are degraded or inhibited by the bifunctional compounds. The invention details compounds that feature a ligand binding to the cereblon E3 ubiquitin ligase on one end and a moiety that binds a target protein on the other end. This design allows the target protein to be positioned near the ubiquitin ligase, facilitating its degradation and inhibition. The compounds can be synthesized to exhibit a wide range of pharmacological activities, making them versatile tools in the degradation and inhibition of targeted polypeptides.
Career Highlights
Momar Toure is currently affiliated with Yale University, where he continues to advance his research in biochemistry and pharmacology. His innovative work has garnered attention in the scientific community, contributing to the understanding of protein degradation mechanisms.
Collaborations
Toure has collaborated with esteemed colleagues such as Craig M Crews and Saul Jaime-Figueroa. These collaborations have further enriched his research and expanded the impact of his inventions.
Conclusion
Momar Toure's contributions to the field of biochemistry through his innovative patents highlight the importance of research in developing new therapeutic strategies. His work exemplifies the potential of targeted ubiquitination in addressing complex biological challenges.